Friday, 19 Jul 2019

You are here

Less Structural Damage with T2T in Gout

A two‐year randomized clinical trial has demonstrated that allopurinol dose escalation to a target serum urate (SU) results in less bone erosion, structural damage and urate crystal deposition in patients with gout.

A prospective, two‐year clinical trial randomized 87 gout patients to received either convential allopurinol dosing or treat-to-target (T2T) dose escalation to achieve a target serum urate < 6mg/dl. Subjects underwent dual energy CT (DECT) scans of the feet, and radiographs (XR, hand and foot) at yearly intervals and DECT scans were scored for bone erosion and urate volume.

After 2 years, CT erosion score was higher in the control group compared in the T2T (+7.8% change vs +1.4% in the T2T group, Prandomization =0.015).

While changes in XRay erosion or narrowing scores did not differ between groups, DECT scans showed that urate volumes in the dose escalation group had reduced DECT urate volume (‐27.6 to ‐28.3%) at year 2 (p=0.023).

These findings provide evidence that imaging evidence that long‐term urate‐lowering therapy, adjusted to achieve a target serum urate can influence structural outcomes in gout.

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Opioids Overused in Acute Gout

Opioids were commonly given to patients as a treatment for acute gout attacks, despite the availability of other effective and appropriate therapies, a retrospective study found.

Allopurinol Fails to Curtail Hypertension

Editor's note: July 1 - 5, RheumNow is running the best of the EULAR 2019 meeting. A novel trial presented at EULAR 2019 last week assessed whether the use of urate-lowering therapy (ULT) would control hypertension in those at risk; however, results of this trial were largely negative.

Hypertension is one of the many comorbidities that plagues gout patients.

Allopurinol Fails to Curtail Hypertension

A novel trial presented at EULAR 2019 last week assessed whether the use of urate-lowering therapy (ULT) would control hypertension in those at risk; however, results of this trial were largely negative.

Hypertension is one of the many comorbidities that plagues gout patients.

Updated 2018 EULAR Recommendations for the Diagnosis of Gout

The first EULAR recommendations for the diagnosis of gout were published in 2006. A task force was formed and following a systematic review, they voted unanimously for changes in all items of the 2006 recommendations.

Excess Non-CV Mortality Persists in Gout

Patients with gout not only have a well-recognized increased risk of dying from cardiovascular (CV) disease, but also have higher all-cause mortality and die prematurely from other diseases, a Swedish study indicated.